Gisela Schwab Biography and Net Worth

CMO of Exelixis

Gisela M. Schwab, M.D., has served as President, Product Development and Medical Affairs and Chief Medical Officer since February 2016. Previously she served as Executive Vice President and Chief Medical Officer from January 2008 to February 2016 and as Senior Vice President and Chief Medical Officer from September 2006 to January 2008. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. From August 2011 through July 2014, Dr. Schwab served as a member of the board of directors of Topotarget A/S, a publicly held biopharmaceutical company. She has served as a member of the board of directors of Cellerant Therapeutics, Inc. a privately held biopharmaceutical company since June 2012, as a member of the board of directors of Genocea Biosciences, Inc., a publicly held biopharmaceutical company, since February 2020, and as a member of the board of directors of Nordic Nanovector A.S. (Nordic), a Norwegian biotechnology company, since March 2015. Dr. Schwab will be stepping down from the Nordic board of directors at Nordic’s next Annual General Meeting in June 2020. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology.

What is Gisela Schwab's net worth?: The estimated net worth of Gisela Schwab is at least $4.93 million as of February 14th, 2019. Dr. Schwab owns 148,180 shares of Exelixis stock worth more than $4,932,912 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Schwab may own. Learn More about Gisela Schwab's net worth.
How do I contact Gisela Schwab?: The corporate mailing address for Dr. Schwab and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Gisela Schwab's contact information.
Has Gisela Schwab been buying or selling shares of Exelixis?: Gisela Schwab has not been actively trading shares of Exelixis during the last ninety days. Most recently, Gisela Schwab sold 100,000 shares of the business's stock in a transaction on Thursday, May 13th. The shares were sold at an average price of $25.38, for a transaction totalling $2,538,000.00. Learn More on Gisela Schwab's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 3 times. They purchased a total of 615,000 shares worth more than $12,668,000.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 739,715 shares worth more than $21,619,607.83. The most recent insider tranaction occured on November, 29th when EVP Jeffrey Hessekiel sold 60,000 shares worth more than $2,200,200.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 11/29/2024.

Gisela Schwab Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/13/2021	Sell	100,000	$25.38	$2,538,000.00
4/26/2021	Sell	50,000	$25.00	$1,250,000.00
4/1/2021	Sell	50,000	$23.00	$1,150,000.00
2/17/2021	Sell	50,000	$22.50	$1,125,000.00
6/4/2020	Sell	100,000	$22.96	$2,296,000.00
4/23/2020	Sell	100,000	$26.00	$2,600,000.00
3/4/2020	Sell	100,000	$19.40	$1,940,000.00
2/19/2020	Sell	40,000	$21.50	$860,000.00
2/7/2020	Sell	50,000	$18.37	$918,500.00
1/7/2020	Sell	50,000	$17.96	$898,000.00
12/3/2019	Sell	50,000	$17.36	$868,000.00
11/4/2019	Sell	50,000	$15.99	$799,500.00
10/1/2019	Sell	30,000	$17.87	$536,100.00
4/3/2019	Sell	63,109	$25.00	$1,577,725.00
3/25/2019	Sell	100,000	$23.14	$2,314,000.00
2/14/2019	Sell	100,000	$21.66	$2,166,000.00	148,180
12/3/2018	Sell	13,499	$21.02	$283,748.98
11/1/2018	Sell	12,000	$14.16	$169,920.00
10/1/2018	Sell	12,000	$17.77	$213,240.00
9/4/2018	Sell	22,500	$18.53	$416,925.00
8/1/2018	Sell	22,500	$20.56	$462,600.00
7/2/2018	Sell	22,500	$21.20	$477,000.00
6/1/2018	Sell	22,500	$20.80	$468,000.00
5/3/2018	Sell	22,500	$23.09	$519,525.00
9/28/2017	Sell	100,000	$23.79	$2,379,000.00
5/1/2017	Sell	89,910	$23.01	$2,068,829.10
12/1/2016	Sell	22,000	$16.73	$368,060.00
8/4/2016	Sell	42,338	$11.00	$465,718.00	174,354
12/10/2012	Buy	25,000	$4.39	$109,750.00

Gisela Schwab Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $33.29

$33.11

$33.68

50 Day Range

MA: $33.51

$26.24

$36.46

2 Week Range

Now: $33.29

$19.20

$36.97

Volume

7,648,822 shs

Average Volume

2,082,318 shs

Market Capitalization

$9.51 billion

P/E Ratio

21.34

Dividend Yield

N/A

Beta

0.52

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.